WW report finds GLP-1 users in its support program lose 61% more weight in one month and 29% more in one year

Reuters03-11

WW report finds GLP-1 users in its support program lose 61% more weight in one month and 29% more in one year

Weight Watchers published a GLP-1 Results Report analyzing outcomes for members using GLP-1 medications alongside its GLP-1 Success Program versus medication alone. The report said regularly engaged Med+ members lost 61% more body weight after one month and 29% more after 12 months than members using medication without additional program engagement. It also reported that Med+ members prescribed GLP-1 medications averaged 21% weight loss at 12 months and 20.5% at 24 months. In a comparative analysis cited, members achieved 72% greater average weight loss than a cohort receiving compounded GLP-1 medications through Hims & Hers. The report said 72% of participants indicated the program helped minimize GLP-1 side effects.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. WW International Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202603110900PRIMZONEFULLFEED9670022) on March 11, 2026, and is solely responsible for the information contained therein.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2618940382?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-11 21:01","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2618940382","market":"us","top_or_hot":-1,"title":"WW report finds GLP-1 users in its support program lose 61% more weight in one month and 29% more in one year","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      WW report finds GLP-1 users in its support program lose 61% more weight in one month and 29% more in one year\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Weight Watchers published a GLP-1 Results Report analyzing outcomes for members using GLP-1 medications alongside its GLP-1 Success Program versus medication alone. The report said regularly engaged Med+ members lost 61% more body weight after one month and 29% more after 12 months than members using medication without additional program engagement. It also reported that Med+ members prescribed GLP-1 medications averaged 21% weight loss at 12 months and 20.5% at 24 months. In a comparative analysis cited, members achieved 72% greater average weight loss than a cohort receiving compounded GLP-1 medications through Hims &amp; Hers. The report said 72% of participants indicated the program helped minimize GLP-1 side effects.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. WW International Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202603110900PRIMZONEFULLFEED9670022) on March 11, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>WW report finds GLP-1 users in its support program lose 61% more weight in one month and 29% more in one year</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWW report finds GLP-1 users in its support program lose 61% more weight in one month and 29% more in one year\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-03-11 21:01</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      WW report finds GLP-1 users in its support program lose 61% more weight in one month and 29% more in one year\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Weight Watchers published a GLP-1 Results Report analyzing outcomes for members using GLP-1 medications alongside its GLP-1 Success Program versus medication alone. The report said regularly engaged Med+ members lost 61% more body weight after one month and 29% more after 12 months than members using medication without additional program engagement. It also reported that Med+ members prescribed GLP-1 medications averaged 21% weight loss at 12 months and 20.5% at 24 months. In a comparative analysis cited, members achieved 72% greater average weight loss than a cohort receiving compounded GLP-1 medications through Hims &amp; Hers. The report said 72% of participants indicated the program helped minimize GLP-1 side effects.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. WW International Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202603110900PRIMZONEFULLFEED9670022) on March 11, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IE00BKPKM429.USD","symbol_name":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260311:nNDL7DWr5b:1","article_id":"2618940382","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2618940382","pubTimestamp":1773234104,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Weight Watchers published a GLP-1 Results Report analyzing outcomes for members using GLP-1 medications alongside its GLP-1 Success Program versus medication alone. The report said regularly engaged Med+ members lost 61% more body weight after one month and 29% more after 12 months than members using medication without additional program engagement. It also reported that Med+ members prescribed GLP-1 medications averaged 21% weight loss at 12 months and 20.5% at 24 months. In a comparative analysis cited, members achieved 72% greater average weight loss than a cohort receiving compounded GLP-1 medications through Hims & Hers. The report said 72% of participants indicated the program helped minimize GLP-1 side effects.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","BK4585":"ETF&股票定投概念","SG9999014039.USD":"UNITED GLOBAL DURABLE EQUITIES (USDHDG) INC","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","HIMY":"Defiance Leveraged Long + Income HIMS ETF","SG9999014005.SGD":"United Global Durable Equities Fund Acc SGD","SG9999014021.USD":"UNITED GLOBAL DURABLE EQUITIES (USDHDG) ACC","HMYY":"GraniteShares YieldBoost HIMS ETF","LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD","HIMZ":"DEFIANCE DAILY TARGET 2X LONG HIMS ETF","IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","SG9999014013.SGD":"United Global Durable Equities Fund Dis SGD","LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H","BK4192":"特殊消费者服务","BK4588":"碎股","LU0314104364.USD":"MANULIFE GF AMERICAN GROWTH \"AA\" (USD) INC","BK4112":"金融交易所和数据","HIYY":"YieldMax HIMS Option Income Strategy ETF","WW":"WW International, Inc.","BK4196":"保健护理服务"},"translate_title":"WW报告发现其支持计划中的GLP-1用户在一个月内体重减轻了61%，在一年内体重减轻了29%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"HIMZ":0.6,"HIYY":0.6,"WW":1.96,"HIMY":0.6,"HMYY":0.6},"content_text":"WW report finds GLP-1 users in its support program lose 61% more weight in one month and 29% more in one year\n    \n\n        Weight Watchers published a GLP-1 Results Report analyzing outcomes for members using GLP-1 medications alongside its GLP-1 Success Program versus medication alone. The report said regularly engaged Med+ members lost 61% more body weight after one month and 29% more after 12 months than members using medication without additional program engagement. It also reported that Med+ members prescribed GLP-1 medications averaged 21% weight loss at 12 months and 20.5% at 24 months. In a comparative analysis cited, members achieved 72% greater average weight loss than a cohort receiving compounded GLP-1 medications through Hims & Hers. The report said 72% of participants indicated the program helped minimize GLP-1 side effects.\n      \n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. WW International Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202603110900PRIMZONEFULLFEED9670022) on March 11, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2618940382","isCrawlerRequest":true}